Case ReportOcular Toxicity Related to Cetuximab Monotherapy in Patients with Colorectal Cancer
References (8)
- et al.
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
Ann Oncol
(2005) - et al.
Trichomegaly of the eyelashes following treatment with cetuximab
Ann Oncol
(2005) - et al.
Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient
J Natl Cancer Inst
(2005) Erbitux™ [package insert]
(2004)
Cited by (20)
Ocular side effects of oncological therapies: Review
2024, Archivos de la Sociedad Espanola de OftalmologiaEmergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know
2022, Cancer Treatment ReviewsCitation Excerpt :OAE frequency and severity: Cetuximab has been associated with dry eye (67%), blepharitis (63%), conjunctivitis (10–18%), and eyelid rash or hyperemia (38%) [6,60]. Other cetuximab associated OAEs in case reports include eye discomfort, foreign body sensation, tearing, and redness [61]. Overall class OAEs are mild and more common AEs include conjunctivitis (5%), growth of eyelashes (6%), blepharitis with increased lacrimation and eyelid irritation reported in 15% of patients [2,62].
Induced drug uveitis and drug side effects in ophthalmology
2018, Revue de Medecine InterneOcular toxicities of MEK inhibitors and other targeted therapies
2016, Annals of OncologyCitation Excerpt :Cetuximab is an EGFR monoclonal antibody used to treat head and neck and advanced colorectal cancer. Multiple different ocular toxicities have been reported with the use of cetuximab, including corneal erosions [6], poliosis [7], eyelash trichomegaly [7–11], punctate keratitis [12], conjunctivitis, eyelid dermatitis and blepharitis [10, 13]. Panitumumab is an EGFR monoclonal antibody used in patients with advanced colorectal cancers.
Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer
2010, European Journal of Oncology NursingCitation Excerpt :Entropion or ectropion: inversion or eversion of the eyelid margin (Burtness et al., 2009) Ocular adverse events in response to anti-EGFR therapy affect approximately 15% of patients treated with cetuximab or panitumumab although severe toxicities are observed in <1% of patients treated with the antibodies as monotherapy (Basti, 2007; Dranko et al., 2006; Erbitux SmPC; Jean and Shah, 2008; Vectibix SmPC). According the Erbitux prescribing information, conjunctivitis was commonly observed with cetuximab, whereas blepharitis and keratitis were uncommon (Erbitux SmPC).
Uncommon Blepharitis
2024, Journal of Clinical Medicine
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1533-0028, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.